Detection of inherited metabolic diseases in children with mental handicap

Chetna Bhatt1, Zarangis Misra, Neelam Goyel

  • 1Genetic Laboratory, Smt. M.T. Research Institute The Research Society, Sewri Hill, Mumbai, 400033 India.

Insights

This study identified causes of developmental delay in 2000 children. Environmental factors (34.6%) and genetic factors (23.8%), including chromosomal abnormalities, were the primary causes of mental retardation.

Area of Science:

  • Pediatrics
  • Genetics
  • Developmental Biology

Background:

  • Mental retardation involves complex intrinsic and extrinsic factors affecting child development.
  • Developmental delay necessitates a multidisciplinary approach for accurate diagnosis.

Purpose of the Study:

  • To investigate the etiological factors contributing to mental retardation in a cohort of 2000 children with developmental delay.
  • To differentiate between genetic, environmental, and idiopathic causes of developmental delay.

Main Methods:

  • A multidisciplinary team (Pediatrician, Cytogeneticist, Biochemist, Psychologist, Therapists) evaluated 2000 cases.
  • Diagnostic categories included genetic, environmental, and idiopathic factors.
  • Specific genetic analyses focused on chromosomal abnormalities and Mendelian inheritance disorders.

Main Results:

  • A definitive diagnosis was achieved in 60% (1192) of cases.
  • Environmental factors accounted for 34.6% (692) of cases, while genetic factors were identified in 23.8% (477).
  • Chromosomal abnormalities were the most frequent genetic cause (17.75%), followed by Mendelian disorders (6.1%).

Conclusions:

  • Multidisciplinary assessment is crucial for diagnosing developmental delay.
  • Environmental and genetic factors, particularly chromosomal abnormalities, are significant contributors to mental retardation.
  • Early detection of inherited metabolic disorders like Mucopolysaccharidosis and amino acid abnormalities is vital.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pedigree Analysis01:35

Pedigree Analysis

Overview
Intellectual Disability01:29

Intellectual Disability

Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
Protein Import into the Peroxisomes01:27

Protein Import into the Peroxisomes

Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...